Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Can adequacy of anesthesia depth and quality of recovery be influenced by the level of neuromuscular blockade: a randomized controlled study assessing propofol and remifentanil requirements and quality of recovery in patients with a standard practice of non-deep rocuronium neuromuscular blockade versus deep neuromuscular blockade reversed with sugammadex.

Trial Profile

Can adequacy of anesthesia depth and quality of recovery be influenced by the level of neuromuscular blockade: a randomized controlled study assessing propofol and remifentanil requirements and quality of recovery in patients with a standard practice of non-deep rocuronium neuromuscular blockade versus deep neuromuscular blockade reversed with sugammadex.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sugammadex (Primary) ; Rocuronium bromide
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 Status changed from recruiting to completed.
    • 09 Mar 2017 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top